Diyuan Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Diyuan Xue has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Hua Peng
Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
2 shared publications - Yang-Xin Fu
Changping Laboratory, Beijing, China
2 shared publications - Benjamin Moon
University of Texas Southwestern Medical Center, Dallas, and University of California, San Francisco
1 shared publication - Jiao Shen
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
1 shared publication - Jing Liao
GMU-GIBH Joint School of Life Sciences, Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China
1 shared publication Jingya Guo
Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
1 shared publication
Latest Publications
- Open Access
- 27 September 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (12)
An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery
Checkpoint blockade immunotherapy releases the inhibition of tumor-infiltrating lymphocytes (TILs) but weakly induces TIL proliferation. Exogenous IL-15 could further expand TILs and thus synergize with αPD-L1 therapy. However, systemic delivery of IL-15 extensively expands peripheral NK cells, causing severe toxicity. To redirect IL-15 to intratumoral PD-1+CD8+T effector cells instead of NK cells for better tumor control and lower toxicity, we engineered an anti–PD-1 fusion with IL-15-IL-15Rα, whose activity was geographically concealed by immunoglobulin Fc region with an engineered linker (αPD-1-IL-15-R) to bypass systemic NK cells. Systematic administration of αPD-1-IL-15-R elicited extraordinary antitumor efficacy with undetectable toxicity. Mechanistically, cis-delivery of αPD-1-IL-15-R vastly expands tumor-specific CD8+T cells for tumor rejection. Additionally, αPD-1-IL-15-R upregulated PD-1 and IL-15Rβ on T cells to create a feedforward activation loop, thus rejuvenating TILs, not only resulting in tumor control in situ, but also suppressing tumor metastasis. Collectively, renavigating IL-15 to tumor-specific PD-1+CD8+T cells, αPD-1-IL-15-R elicits effective systemic antitumor immunity.
- 27 September 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (12)
Open AccessAn engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery
Checkpoint blockade immunotherapy releases the inhibition of tumor-infiltrating lymphocytes (TILs) but weakly induces TIL proliferation. Exogenous IL-15 could further expand TILs and thus synergize with αPD-L1 therapy. However, systemic delivery of IL-15 extensively expands peripheral NK cells, causing severe toxicity. To redirect IL-15 to intratumoral PD-1+CD8+T effector cells instead of NK cells for better tumor control and lower toxicity, we engineered an anti–PD-1 fusion with IL-15-IL-15Rα, whose activity was geographically concealed by immunoglobulin Fc region with an engineered linker (αPD-1-IL-15-R) to bypass systemic NK cells. Systematic administration of αPD-1-IL-15-R elicited extraordinary antitumor efficacy with undetectable toxicity. Mechanistically, cis-delivery of αPD-1-IL-15-R vastly expands tumor-specific CD8+T cells for tumor rejection. Additionally, αPD-1-IL-15-R upregulated PD-1 and IL-15Rβ on T cells to create a feedforward activation loop, thus rejuvenating TILs, not only resulting in tumor control in situ, but also suppressing tumor metastasis. Collectively, renavigating IL-15 to tumor-specific PD-1+CD8+T cells, αPD-1-IL-15-R elicits effective systemic antitumor immunity.
- 7 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (67) , eabi6899
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
A tumor-specific pro-IL-12 rejuvenated preexisting TILs to induce tumor growth delay without inducing systemic toxicity.
- 7 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (67) , eabi6899
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
A tumor-specific pro-IL-12 rejuvenated preexisting TILs to induce tumor growth delay without inducing systemic toxicity.